Trial Profile
A Randomized, Open-label, Active-controlled, Multicenter Phase 3 Study to Investigate the Efficacy and Safety of Roxadustat for Treatment of Anemia in Subjects Receiving Chemotherapy Treatment for Non-Myeloid Malignancies
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 29 Feb 2024
Price :
$35
*
At a glance
- Drugs Roxadustat (Primary) ; Recombinant erythropoietin
- Indications Chemotherapy-induced anaemia
- Focus Registrational; Therapeutic Use
- Sponsors FibroGen
- 26 Feb 2024 According to a FibroGen media release, company expect approval decision for roxadustat in chemotherapy-induced anemia (CIA) in China in mid-2024. If approved, FibroGen will receive a $10M milestone payment from AstraZeneca.
- 24 Oct 2023 Results (n=140) assessing the efficacy and safety of roxadustat for anemia in patients with non-myeloid malignancies receiving multi-cycle treatments of myelosuppressive chemotherapy presented at the 48th European Society for Medical Oncology Congress
- 05 Jun 2023 Status changed from active, no longer recruiting to completed.